{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:53:50Z","timestamp":1791003230947,"version":"4.1.0"},"reference-count":18,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,9,30]]},"DOI":"10.1536\/ihj.26-175","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:10:42Z","timestamp":1789078242000},"page":"458-463","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Real-World Outcomes of Hypertrophic Cardiomyopathy Patients Undergoing ICD Implantation"],"prefix":"10.1536","volume":"67","author":[{"given":"Yoshiyasu","family":"Aizawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Okajima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Hachisuka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukichi","family":"Tokita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yodogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ki","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniya","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60: 705-15.","DOI":"10.1016\/j.jacc.2012.02.068"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Maron BJ, Towbin JA, Thiene G, <i>et al<\/i>. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-16.","DOI":"10.1161\/CIRCULATIONAHA.106.174287"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chen Y, Luo S, Li J, Zhang H. Emerging Trends in Hypertrophic Cardiomyopathy Research. Int Heart J 2026; 67: 43-52.","DOI":"10.1536\/ihj.25-257"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Aizawa Y, Tanimoto Y, Hirata Y, <i>et al<\/i>. Incidence, Clinical Characteristics, and Long-term Outcome of the Dilated Phase of Hypertrophic Cardiomyopathy. Keio J Med 2019; 68: 87-94.","DOI":"10.2302\/kjm.2018-0004-OA"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ommen SR, Mital S, Burke MA, <i>et al<\/i>. 2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142: e558-631.","DOI":"10.1161\/CIR.0000000000000945"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Olde Nordkamp LR, Postema PG, Knops RE, <i>et al<\/i>. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm 2016; 13: 443-54.","DOI":"10.1016\/j.hrthm.2015.09.010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bardy GH, Smith WM, Hood MA, <i>et al<\/i>. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363: 36-44.","DOI":"10.1056\/NEJMoa0909545"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Weiss R, Knight BP, Gold MR, <i>et al<\/i>. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 2013; 128: 944-53.","DOI":"10.1161\/CIRCULATIONAHA.113.003042"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. da Silva Menezes Junior A, Oliveira IC, de Sousa AM, Paro Piai RF, Oliveira VMR. Subcutaneous versus transvenous implantable cardioverter defibrillator in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Cardiovasc Diagn Ther 2024; 14: 318-27.","DOI":"10.21037\/cdt-24-15"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Jankelson L, Garber L, Sherrid M, <i>et al<\/i>. Subcutaneous versus transvenous implantable defibrillator in patients with hypertrophic cardiomyopathy. Heart Rhythm 2022; 19: 759-67.","DOI":"10.1016\/j.hrthm.2022.01.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Authors\/Task Force m, Elliott PM, Anastasakis A, <i>et al<\/i>. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-79.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Maron BJ, Rowin EJ, Casey SA, <i>et al<\/i>. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol 2015; 65: 1915-28.","DOI":"10.1016\/j.jacc.2015.02.061"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Burke MC, Gold MR, Knight BP, <i>et al<\/i>. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015; 65: 1605-15.","DOI":"10.1016\/j.jacc.2015.02.047"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Gold MR, Aasbo JD, El-Chami MF, <i>et al<\/i>. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm 2017; 14: 1456-63.","DOI":"10.1016\/j.hrthm.2017.05.016"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Thompson AE, Christie M, Lentz L. Substernal Extravascular Implantable Cardioverter-Defibrillator System Infections in Large Animals. Int Heart J 2023; 64: 724-31.","DOI":"10.1536\/ihj.22-553"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kimura A. Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet 2016; 61: 41-50.","DOI":"10.1038\/jhg.2015.83"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Inagaki N, Hayashi T, Takei Y, Tanimoto K, Chikamori T, Kimura A. Clinical and genetic backgrounds of hypertrophic cardiomyopathy with mid-ventricular obstruction. J Hum Genet 2018; 63: 1273-6.","DOI":"10.1038\/s10038-018-0509-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hayashi T. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy. Keio J Med 2020; 69: 77-87.","DOI":"10.2302\/kjm.2019-0012-OA"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/5\/67_26-175\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:25:09Z","timestamp":1791001509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/5\/67_26-175\/_article"}},"subtitle":["A Single-Center Experience with Transvenous and Subcutaneous Systems"],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.26-175","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"26-175"}}